Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
about
Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.Barrett's oesophagus: from metaplasia to dysplasia and cancerCurrent concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ systemEpidemiology of Barrett's Esophagus and Esophageal AdenocarcinomaClinical significance and management of Barrett's esophagus with epithelial changes indefinite for dysplasiaBarrett's oesophagus: frequency and prediction of dysplasia and cancerSecondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trialThe framework of pathology: good laboratory practice by quantitative and molecular methods.Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up.Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness.Elastic scattering spectroscopy accurately detects high grade dysplasia and cancer in Barrett's oesophagusThree-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy.History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus.Medical and endoscopic management of high-grade dysplasia in Barrett's esophagusBarrett's esophagus and the increasing role of endoluminal therapy.Diagnosis and grading of dysplasia in Barrett's oesophagus.Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma.The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis.DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagusRoutine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett's oesophagus surveillance biopsiesAntireflux surgery for Barrett's oesophagus.The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinomaAssociation of promoter methylation of RUNX3 gene with the development of esophageal cancer: a meta analysis.HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas.Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniquesChromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.The prevalence of Barrett's-esophagus-associated dysplasia in Puerto Rico.American Gastroenterological Association technical review on the management of Barrett's esophagusDrinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full!Expression of p53 predicts risk of prevalent and incident advanced neoplasia in patients with Barrett's esophagus and epithelial changes indefinite for dysplasia.Barrett's Esophagus: Emerging Knowledge and Management StrategiesDetection of endogenous biomolecules in Barrett's esophagus by Fourier transform infrared spectroscopy.New developments in the endoscopic surveillance of Barrett's oesophagusEndoscopic therapy for Barrett's oesophagus.Predictors of progression in Barrett's esophagus: current knowledge and future directionsPhotodynamic therapy for Barrett's esophagus with high-grade dysplasia.Barrett's esophagus: A review of diagnostic criteria, clinical surveillance practices and new developments.
P2860
Q24642374-5286437A-AD58-44BE-8BAE-8597FD2243A9Q24685867-158690DB-5079-46FF-9771-77E4D718A04BQ26748510-45712E92-F95A-4DF7-9120-17AF9D07AA19Q26825742-C3881CDD-9272-492C-B241-D31FD8B64E9CQ28078968-2F1BF326-8777-4069-B6DD-4B91C15A2967Q28080794-3A9A38C8-64AC-4894-B230-5568959773B1Q28222007-ABEC3EBA-8BF5-4F9D-BD11-C390CACAA3ABQ30862047-B5F7296D-FF19-49CA-8008-F37DAA8BF5F5Q32060710-12F90FB1-62A9-4330-B55F-A540544382CFQ33222183-22E47D55-F9F7-43A6-8169-EFDA64FD7905Q33233577-FF8FC82C-50E3-4BAE-9445-FC734DF39986Q33326627-4427CB15-8E4A-4151-82DA-EC1334ED56FFQ33575943-2A1FA9A4-B46E-428A-A3A4-236C841C7C0CQ33786336-5FDAFC03-8896-483D-8293-D10FA885A88AQ33869648-580E2E69-C832-4A6D-BE53-C8CB3795D0EFQ34024948-7FA29AF5-5C6F-4CAD-97A5-33C7131999D3Q34050233-B8DF7A6A-E83C-4F11-8017-A9EE2CA36C40Q34408906-C348C855-21AC-442F-A2CF-A4CCDE2A3C5FQ34571587-78B62C96-997B-423C-9A58-8977FF4DB64FQ34703662-C480151B-7133-4CB0-913E-AFE4C203D7A6Q34786281-2D887345-076A-4787-9120-AA6E84CCB08BQ34958192-49337AB4-F9B7-4DA1-811C-A0E8ABC7A8E8Q35013674-80C3EF17-2A51-489D-B776-76CA50D94128Q35093686-1D889DCF-CC38-4D2A-84B1-06F2EB679B5FQ35125620-2AB6BC37-CB6D-4061-BE4A-5C55B2D26150Q35257951-47968E03-C9C5-4121-9EC8-5607BF54721DQ35548468-645F38DC-4969-4D6B-83A3-A219DEAFD883Q35595332-6859E471-C993-4C89-A6AE-7DE5A56D6D0EQ35595606-10872B16-2F6E-4FE3-870B-59E90BB8E420Q35619274-86B3E143-48A2-4A5A-9336-C6C1E549C09DQ35673305-47486543-EC06-4591-8B7F-A6F80BB52FB6Q35760913-E79ADB80-8076-4895-8CA5-79BA6BCFA651Q35815186-FB719874-CF5D-45ED-83F3-FF4E58DA4116Q36014649-3B294EF9-8918-40C2-8D71-17098FC6DF10Q36023728-5AFDE0C5-A17F-45AC-BAF7-A1DDDCFDB09BQ36041670-9B011F28-8158-4F87-B955-C917D545166AQ36124437-3F49F116-C8A7-4350-805D-4A1AF8211DC3Q36127891-0A2B3FB2-2E10-4D52-8EA1-742B78A52616Q36131795-72C0AA40-1A32-4DBB-8A93-77D0DB5CEB5DQ36162518-383BE9B2-F5DC-4104-8FCA-63977CADDD97
P2860
Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Dysplasia as a predictive mark ...... diagnostic variability study.
@ast
Dysplasia as a predictive mark ...... diagnostic variability study.
@en
Dysplasia as a predictive mark ...... diagnostic variability study.
@nl
type
label
Dysplasia as a predictive mark ...... diagnostic variability study.
@ast
Dysplasia as a predictive mark ...... diagnostic variability study.
@en
Dysplasia as a predictive mark ...... diagnostic variability study.
@nl
prefLabel
Dysplasia as a predictive mark ...... diagnostic variability study.
@ast
Dysplasia as a predictive mark ...... diagnostic variability study.
@en
Dysplasia as a predictive mark ...... diagnostic variability study.
@nl
P2093
P356
P1433
P1476
Dysplasia as a predictive mark ...... diagnostic variability study.
@en
P2093
Goldblum JR
Greenson JK
Lauwers GY
Lazenby AJ
Montgomery E
P304
P356
10.1053/HUPA.2001.23511
P407
P577
2001-04-01T00:00:00Z